

COPY OF PAPERS
ORIGINALLY FILED

#12 9A4 1645

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)
Approved for use through 10/31/02. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/039,059
Filing Date	December 31, 2001
First Named Inventor	Ton LOGTENBERG
Group Art Unit	1645
Examiner Name	To Be Assigned
Attorney Docket No.	313632000801

RECEIVED

JUN 11 2002

TECH CENTER 1600/2900

Total Number Of Pages In This Submission

8

ENCLOSURES (check all that apply)

- | | | |
|--|--|---|
| <input type="checkbox"/> Fee Transmittal Form | <input type="checkbox"/> Assignment Papers
(for an Application) | <input type="checkbox"/> After Allowance Communication to Group |
| <input type="checkbox"/> Fee Attached | <input type="checkbox"/> Drawing(s) | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences |
| <input type="checkbox"/> Amendment / Reply | <input type="checkbox"/> Licensing-related Papers | <input type="checkbox"/> Appeal Communication to Group
(Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final | <input type="checkbox"/> Petition | <input type="checkbox"/> Proprietary Information |
| <input type="checkbox"/> Affidavits/declarations | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Status Letter |
| <input type="checkbox"/> Extension of Time Request | <input type="checkbox"/> Power of Attorney, Revocation
Change of Correspondence Address | <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return postcard |
| <input type="checkbox"/> Express Abandonment Request | <input type="checkbox"/> Terminal Disclaimer | |
| <input checked="" type="checkbox"/> Information Disclosure Statement;
PTO form 1449 | <input type="checkbox"/> Request for Refund | |
| <input type="checkbox"/> Certified Copy of Priority Document(s) | <input type="checkbox"/> CD, Number of CD(s) _____ | |
| <input type="checkbox"/> Response to Missing Parts/
Incomplete Application | | |
| <input type="checkbox"/> Response to Missing Parts
under 37 CFR 1.52 or 1.53 | | |

Remarks

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm
or
Individual Name

Kate H. Murashige
Registration No. 29,959

Signature

Kate H. Murashige

Date

May 23, 2002

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on May 23, 2002.

Garee A. Haney
Garee A. Haney

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



PATENT
Docket No. 313632000801

8.522
#12

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on May 23, 2002.

Garee A. Haney
Garee A. Haney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Ton LOGTENBERG and Cornelis
Andriaan DE KRUIF

Serial No.: 10/039,059

Filing Date: December 31, 2001

For: ALTERING THE PROPERTIES OF
CELLS OR OF PARTICLES WITH
MEMBRANES DERIVED FROM
CELLS BY MEANS OF LIPID-
MODIFIED PROTEINACEOUS
MOLECULES

Examiner: To Be Assigned

Group Art Unit: 1645

RECEIVED

JUN 11 2002

TECH CENTER 1600/2900

**COPY OF PAPERS
ORIGINALLY FILED**

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 09/418,563, filed October 15, 1999, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R.

§1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of * is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of * is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 313632000801. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: May 23, 2002

Respectfully submitted,

By: Kate H. Murashige
Kate H. Murashige
Registration No. 29,959

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 313632000801

Application Number 10/039,059

Applicant

Ton LOGTENBERG and Cornelis Andriaan DE KRUIF

Filing Date December 31, 2001

Group Art Unit 1645

Mailing Date May 23, 2002

RECEIVED

COPY OF PAPERS
ORIGINALLY FILED

JUN 11 2002

U.S. PATENT DOCUMENTS

TECH CENTER 1600/2900

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	12/1994	5,374,548	Caras	424	450	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	2.	Abken, H. <i>et al.</i> "Can combined T-cell- and antibody-based immunotherapy outsmart tumor cells?" <i>Trends [in] Immunology Today</i> (January 1998) 19(1):2-5
	3.	Abken, H. <i>et al.</i> "Chimeric T-cell receptors: highly specific tools to target cytotoxic T-lymphocytes to tumor cells," <i>Cancer Treatment Reviews</i> (1997) 23:97-112
	4.	Bennett, S. R. M. <i>et al.</i> "Help for cytotoxic-T-cell responses is mediated by CD40 signalling," <i>Nature</i> (4 June 1998) 393:478-480, <i>Letters to Nature</i>
	5.	Berd, D. <i>et al.</i> "Autologous, Hapten-Modified Vaccine as a Treatment for Human Cancers," <i>Seminars in Oncology</i> (December 1998) 25(6):646-653
	6.	Boder, E. T. <i>et al.</i> "Yeast surface display for screening combinatorial polypeptide libraries," <i>Nature Biotechnology</i> (June 1997) 15:553-557
	7.	Brocker, T. <i>et al.</i> "New simplified molecular design for functional T cell receptor," <i>Eur J Immunol</i> (1993) 23:1435-1439
	8.	De Kruif, J. <i>et al.</i> "Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes," <i>FEBS Letters</i> (1996) 399:232-236
	9.	De Kruif, J. <i>et al.</i> "Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library," <i>Proc Natl Acad Sci USA</i> (April 1995) 92:3938-3942
	10.	De Kruif, J. <i>et al.</i> "Selection and Application of Human Single Chain Fv Antibody Fragments from a Semi-synthetic Phage Antibody Display Library with Designed CDR3 Regions," <i>J Mol Biol</i> (1995) 248:94-105

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

RECEIVED

PTO/SB/08 (2-92)

Sheet 2 of 4

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 313632000801

Application Number 10/039,059

Applicant

TECH CENTER 1600/2900
Ton LOUENBERG and Correns Andriaan DE KRUIF

Filing Date December 31, 2001

Group Art Unit 1645

Mailing Date May 23, 2002

COPY OF PAPERS
ORIGINALLY FILED

- | | |
|-----|--|
| 11. | Devitt, A. <i>et al.</i> "Human CD14 mediates recognition and phagocytosis of apoptotic cells," <i>Nature</i> (2 April 1998) 392:505-509 |
| 12. | Escola, J-M. <i>et al.</i> "Selective Enrichment of Tetraspan Proteins on the Internal Vesicles of Multivesicular Endosomes and on Exosomes Secreted by Human B-lymphocytes," <i>The Journal of Biological Chemistry</i> (August 7, 1998) 279(32):20121-20127 |
| 13. | Eshhar, Z. "Tumor-specific T-bodies: towards clinical application," <i>Cancer Immunol Immunother</i> (1997) 45:131-136 |
| 14. | Eshhar, Z. <i>et al.</i> "Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors," <i>Proc Natl Acad Sci USA</i> (January 1993) 90:720-724 |
| 15. | Francisco, J. A. <i>et al.</i> "Transport and anchoring of β -lactamase to the external surface of <i>Escherichia coli</i> ," <i>Proc Natl Acad Sci USA</i> (April 1992) 89:2713-2717 |
| 16. | Freeman, S. M. <i>et al.</i> "Immune system in suicide-gene therapy," <i>The Lancet</i> (January 4, 1997) 349:2-3 |
| 17. | Gage, F. H. "Cell Therapy," <i>Nature</i> (30 April 1998) 392 Supp.:18-24 |
| 18. | Ghrayeb, J. <i>et al.</i> "Nine Amino Acid Residues at the NH ₂ -terminal of Lipoprotein Are Sufficient for Its Modification, Processing, and Localization in the Outer Membrane of <i>Escherichia coli</i> ," <i>The Journal of Biological Chemistry</i> (January 10, 1984) 259(1):463-487 |
| 19. | Gong, J. <i>et al.</i> "Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells," <i>Nature Medicine</i> (May 1997) 3(5):558-561 |
| 20. | Gosselin, E. J. <i>et al.</i> "Enhanced Antigen Presentation Using Human Fc γ Receptor (Monocyte/Macrophage)-Specific Immunogens," <i>The Journal of Immunology</i> (December 1, 1992) 149(14):3477-3481 |
| 21. | Graziano, R. F. <i>et al.</i> "Construction and Characterization of a Humanized Anti- γ -Ig Receptor Type I (Fc γ RI) Monoclonal Antibody," <i>The Journal of Immunology</i> (1995) 155:4996-5002 |
| 22. | Grouard, G. <i>et al.</i> "Human Follicular Dendritic Cells Enhance cytokine-Dependent Growth and Differentiation of CD40-Activated B Cells," <i>The Journal of Immunology</i> (1995) 155:3345-3352 |
| 23. | Grouard, G. <i>et al.</i> "Human Follicular Dendritic Cells Enhance Cytokine-Dependent Growth and Differentiation of CD40-Activated B Cells," <i>the Journal of Immunology</i> (1995) 155:3345-3352 |
| 24. | Haas, C. <i>et al.</i> "An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules," <i>Cancer Gene Therapy</i> (1999) 6(3):254-262 |
| 25. | Houghton, A. N. "Cancer Antigens: Immune Recognition of Self and Altered Self," <i>J Exp Med</i> (July 1994) 180:1-4, <i>Commentary</i> |
| 26. | Hwu, P. <i>et al.</i> "In Vivo Antitumor Activity of T Cells Redirected with Chimeric Antibody/T-Cell Receptor Genes," <i>Cancer Research</i> (August 1, 1995) 55:3369-3373 |
| 27. | Jin, L. <i>et al.</i> "Targeted expansion of genetically modified bone marrow cells," <i>Proc Natl Acad Sci</i> |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 313632000801

Application Number 10/039,059

Applicant

Ton LOGTENBERG and Cornelis Andriaan DE KRIJFF

Filing Date December 31, 2001

Group Art Unit 1645

Mailing Date May 23, 2002

JUN 11 2002

RECEIVED

USA (July 1998) 95:8093-8097

TECH CENTER 1600/2900


COPY OF PAPERS
ORIGINALLY FILED

- | | |
|-----|---|
| 28. | Kafri, T. <i>et al.</i> "Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors," <i>Nature Genetics</i> (November 1997) 17:314-317, <i>Letter</i> |
| 29. | Keene, J-A. <i>et al.</i> "Helper Activity is Required for the In Vivo Generation of Cytotoxic T Lymphocytes," <i>J Exp Med</i> (March 1982) 155:768-782 |
| 30. | Kwiatkowska, K. <i>et al.</i> "Signaling pathways in phagocytosis," <i>BioEssays</i> (1999) 21:422-431 |
| 31. | Laukkanen, M-L., <i>et al.</i> "Functional Immunoliposomes Harboring a Biosynthetically Lipid-Tagged Single-Chain Antibody," <i>Biochemistry</i> (1994) 33:11664-11670 |
| 32. | Laukkanen, M-L., <i>et al.</i> "Lipid-tagged antibodies: bacterial expression and characterization of a lipoprotein-single-chain antibody fusion protein," <i>Protein Engineering</i> (1993) 6(4):449-454 |
| 33. | Liu, C. <i>et al.</i> "FcγRI-Targeted Fusion Proteins Result in Efficient Presentation by Human Monocytes of Antigenic and Antagonist T Cell Epitopes," <i>J Clin Invest</i> (November 1996) 98(9):2001-2007 |
| 34. | Melcher, A. <i>et al.</i> "Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression," <i>Nature Medicine</i> (May 1998) 4(5):581-587 |
| 35. | Nawrocki, S. <i>et al.</i> "Genetically modified tumour vaccines -- where we are today," <i>Cancer Treatment Reviews</i> (1999) 25:29-46 |
| 36. | Pack, P. <i>et al.</i> "Improved Bivalent Mini-antibodies, with Identical Avidity as Whole Antibodies, Produced by High Cell Density Fermentation of <i>E. coli</i> ," <i>Bio/Technology</i> (November 1993) 11:1271-1277 |
| 37. | Ridge, J. P. <i>et al.</i> "A conditioned dendritic cell can be a temporal bridge between a CD4 ⁺ T-helper and a T-killer cell," <i>Nature</i> (4 June 1998) 393:474-477 |
| 38. | Rosenberg, S. A. "The Immunotherapy and Gene Therapy of Cancer," <i>Journal of Clinical Oncology</i> (February 1992) 10(2):180-199, KARNOFSKY MEMORIAL LECTURE |
| 39. | Rosenberg, S. A. <i>et al.</i> "Use of tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma, A Preliminary Report," <i>The New England Journal of Medicine</i> (Dec. 22, 1988) 319(25):1676-1680, SPECIAL REPORT |
| 40. | Rusiñol, A. E. <i>et al.</i> "In Vitro Reconstitution of Assembly of Apolipoprotein B48-containing Lipoproteins," <i>The Journal of Biological Chemistry</i> (March 21, 1997) 272(12):8019-8025 |
| 41. | Sallusto, F. <i>et al.</i> "Efficient Presentation of Soluble Antigen by Cultured Human Dendritic Cells Is Maintained by Granulocyte/Macrophage Colony-stimulating Factor Plus Interleukin 4 and Downregulated by Tumor Necrosis Factor α," <i>J Exp Med</i> (April 1994) 179:1109-1118 |
| 42. | Schirmacher, V. <i>et al.</i> "Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus," <i>Gene Therapy</i> (1999) 6:63-73 |
| 43. | Schoenberger, S. P. <i>et al.</i> "T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions," <i>Nature</i> (4 June 1998) 393:480-483, <i>Letters to Nature</i> |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 313632000801

Application Number 10/039,059

Applicant

Ton LOGTENBERG and Cornelis Andriaan DE KRUIF

Filing Date December 31, 2001

Group Art Unit 1645

Mailing Date May 23, 2002

- | | |
|-----|--|
| 44. | Simons, K. <i>et al.</i> "Functional rafts in cell membranes," <i>Nature</i> (5 June 1997) 387:569-572 |
| 45. | Smith, G. P. "Filamentous fusion Phage: Novel Expression Vectors That Display Cloned Antigens on the Virion Surface," <i>Science</i> (14 June 1985) 228:1315-1317 |
| 46. | Udenfriend, S. <i>et al.</i> "How Glycosyl-Phosphatidylinositol-Anchored Membrane Proteins are Made," <i>Annu Rev Biochem</i> (1995) 64:563-591 |
| 47. | Vermorken, J. B. <i>et al.</i> "Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial," <i>The Lancet</i> (1999) 353:345-50 |
| 48. | Yee, C. <i>et al.</i> "Prospects for adoptive T cell therapy," <i>Current Opinion in Immunology</i> (1997) 9:702-708 |
| 49. | Zitvogel, L. <i>et al.</i> "Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes," <i>Nature Medicine</i> (May 1998) 4(5):594-600 |

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

JUN 11 2002

TECH CENTER 1600/2900

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.